Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Commentaries on Cutting Edge Science

Wrestling With Heart Failure

SUMO-1 to the Rescue

Pimprapa Vejpongsa, Edward T.H. Yeh
Download PDF
https://doi.org/10.1161/CIRCRESAHA.114.304125
Circulation Research. 2014;114:1561-1563
Originally published May 8, 2014
Pimprapa Vejpongsa
From the Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston (P.V., E.T.H.Y.); and Texas Heart Institute, Houston (E.T.H.Y.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward T.H. Yeh
From the Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston (P.V., E.T.H.Y.); and Texas Heart Institute, Houston (E.T.H.Y.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Introduction
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Introduction

SUMO-1 Gene Transfer Improves Cardiac Function in a Large-Animal Model of Heart Failure

Tilemann et al

Sci Transl Med. 2013;5:211ra159.

A small ubiquitin-like protein was shown to be beneficial to the failing heart through enhancing sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) stability and activity in a large animal model of heart failure.

Dysregulation of calcium cycling in cardiomyocytes has been recognized as a major molecular mechanism of heart failure. SERCA2a plays a pivotal role in regulating calcium homeostasis, and reduction of SERCA2a activity has been recognized as a hallmark of heart failure. Hajjar and his colleagues1 reported that the activity of SERCA2a is regulated by conjugation of small ubiquitin-like modifier-1 (SUMO-1) to SERCA2a. They also demonstrated that SUMO-1 gene delivery can restore SERCA2a expression and activity in the failing heart in a mouse model. Based on these findings, they postulated that SUMO modification (SUMOylation) is a critical regulator of SERCA2a function, which led to the design of SUMO-1 gene therapy in a swine ischemia–reperfusion heart failure model.2 The authors performed a temporary balloon occlusion of the proximal left anterior descending artery to create myocardial infarction. One month later, 31 survived pigs were randomized to receive via antegrade coronary infusion either saline or adeno-associated vector type 1 (AAV1) loaded with SUMO-1 (low and high dose), SERCA2a, or both. They showed that both SUMO-1 and SERCA2a levels were increased in the pigs that received AAV1.SUMO-1 with or without AAV1.SERCA2a 2 months later. However, the changes in left ventricular ejection fraction (EF) were not statistically significant in all treated groups. Statistically significant changes were demonstrated in the maximal rate of pressure rise [dP/dt(max)] in the groups that received high-dose SUMO-1, SERCA2a, or both. Furthermore, the treated groups have less left ventricular dilatation. The authors concluded that SUMO-1 gene either alone or in combination with SERCA2a is beneficial in a large animal model of heart failure and holds promise for the treatment of heart failure in humans.

SERCA2a is a calcium-ion pump that takes up calcium from the cytosol into the sarcoplasmic reticulum.3 The expression level and activity of SERCA2a were found to be diminished in the failing heart.4 In contrast to the well-known SERCA2a, SUMO is relatively unknown to the cardiovascular research community. SUMO belongs to a family of ubiquitin-like proteins that covalently attached to a large number of cellular proteins. SUMOylation is a versatile post-translational protein modification system that regulates a protein’s cellular localization, function, and stability.5 There are 3 different SUMOs: SUMO-1, SUMO-2, and SUMO-3 (Figure). SUMO-2 and SUMO-3 are closely related and are usually described as SUMO-2/3. SUMO-1 usually modifies its substrate as a monomer, whereas SUMO-2 or SUMO-3 can build up poly-SUMO chains. Similar to phosphorylation and dephosphorylation, SUMO modification can be removed by a family of Sentrin/SUMO-specific proteases. SUMOylation and de-SUMOylation have been shown to play critical roles in cell biology, including development, DNA replication/repair, and the hypoxic response.6–8 Interestingly, several cardiac transcription factors are SUMOylated and their transcriptional activities are altered by SUMOylation.9

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

SUMOylation and de-SUMOylation. SUMO modification is a dynamic process that regulates many biological functions. The conjugation of SUMO to the target proteins required the activating enzyme (E1), conjugating enzyme (E2), and ligating enzyme (E3). SUMO/Sentrin-specific proteases (SENPs) deconjugate SUMO from SUMO-conjugated proteins. DRP1 indicates dynamin-related protein 1; ERK5, extracellular signal-regulated kinase 5; GATA4, GATA binding protein 4; MEF2C, myocyte enhancer factor 2C; NKX2.5, NK2 homeobox 5; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARα, peroxisome proliferator-activated receptor alpha; PPARγ, peroxisome proliferator-activated receptor gamma; SERCA2a, sarcoplasmic reticulum Ca2+ ATPase 2a; and SRF, serum response factor.

The authors first demonstrate that AAV1.SUMO-1 restores the expression of SUMO-1 and SERCA2a in the failing heart. This occurs at both the mRNA and protein levels. Furthermore, SUMOylated SERCA2a is markedly increased in the group that received both SUMO-1 and SERCA2a. This is because of the persistence of AAV1 in the cardiac tissues 2 months after gene delivery. Despite restoration of SUMO-1 and SERCA2a expression, changes in EF only showed a trend toward improvement in the high-dose SUMO-1 group as compared with control but did not reach statistically significance. The authors argued that the improvements on the molecular level may precede the functional benefits. One wonders whether a longer observation period could demonstrate a statistically significant improvement in the EF in the treated group.

Hajjar and his colleagues10 previously reported in a phase 1/2 human gene therapy trial using AAV1.SERCA2a that patients treated with high-dose SERCA2a have marked reduction in all-cause mortality. The number of cardiovascular events, such as myocardial infarction, worsening heart failure, ventricular assist device placement, cardiac transplantation, and death, was also reduced in the low- and mid-dose group as compared with placebo control. However, EF was not reported in the 3-year follow-up but was not statistically significant at 12-month follow up.10,11 Thus, EF improvement was not seen in either SERCA2a- or SUMO-1–based gene therapy in human. If EF changes are not significant in both the animal model and the human studies, how does SERCA2a or SUMO-1 gene therapy benefits the failing heart? In this article, the authors showed that there was a statistically significant improvement in cardiac contractility as measured by dP/dt(max) and left ventricular volume.2 Thus, the mechanism whereby SUMO-1 gene therapy benefits the failing heart may be because of a beneficial effect on cardiac remodeling. It is more difficult to explain why improvement in contractility failed to translate into a better EF. Perhaps, the number of the animals studied was too small to reach that conclusion.

The authors provided limited analysis on the mechanisms whereby SUMO-1 gene therapy exerted its beneficial effect. They showed that specificity protein 1 (SP1), a transcription factor for SERCA2a, is markedly increased in the saline group but returned toward normal in the treated group, and SUMOylated SP1 is increased in high-dose SUMO-1–treated group. They suggested that the increase in SUMOylated SP1 is responsible for the increase in SERCA2a mRNA in the treated groups. In contrast to the increase in the stability of SUMOylated SERCA2a, SUMO-1–modified SP1 actually leads to its degradation in a ubiquitin-dependent manner.12 SUMOylated SP1 was shown to be localized in the cytosol and thus will not enhance transcription. In another study, SUMOylation has been shown to inhibit the cleavage of the SP1 N-terminal negative regulatory domain and SP1-dependent transcription.13 Thus, the increase in SUMOylated SP1 in the SUMO-1–treated group could not account for the increase in SERCA2a mRNA. It is more likely that SUMO-1 increases the stability of SERCA2a directly and enhances its ATPase activity as shown by the authors’ previous report.1

SUMO-1 can modify many cellular proteins and could exert its beneficial effect in the failing heart in >1 way. The authors showed that the proform of caspase 3 is reduced in the treated group. One possible scenario is that SUMO-1 may exert an antiapoptotic effect on the dying cardiomyocytes. Interestingly, SUMO-1 was identified originally by us as Sentrin, a protein that protected cell from Fas ligand or tumor necrosis factor–mediated apoptosis.14 We showed that SUMO-1 binds to the death domains of both FAS and tumor necrosis factor receptor and prevents signaling leading to apoptosis. Thus, overexpression of SUMO-1 could protect the cardiomyocytes from cell death, which could reduce cardiac remodeling and preserve cardiac contractility.

An important question to be answered is why SUMO-1 expression is lowered in the failing heart. Additional research is necessary to identify the signaling pathway and transcription factors that are involved in the downregulation of the SUMO-1 gene transcription. It would be much easier to use a small molecule to increase the transcription of SUMO-1 in lieu of SUMO-1 gene therapy. The authors have shown previously that SUMOylation prevents the degradation of SERCA2a.1 Thus, another potential therapeutic approach is to block SERCA2a degradation with a proteasome inhibitor. Indeed, proteasome inhibitors have been shown to exert a beneficial effect on the failing heart.15 The downside of the proteasome inhibitor approach is the lack of specificity and potential pleiotropic effects. If the goal is to increase SUMOylation of SERCA2a, one can reduce the expression and activity of Sentrin/SUMO-specific proteases that are specific for SERCA2a. Alternatively, one can increase the expression and activity of a SERCA2a-specific E3 ligase. In summary, Tilemann and his colleagues2 have introduced an innovative approach to treat heart failure. Although additional investigations are required, we are hopeful that SUMO-1 gene therapy or strategies to increase SUMO-1 level may provide new therapy for patients with heart failure in the future.

Disclosures

None.

Footnotes

  • The opinions expressed in this Commentary are not necessarily those of the editors or of the American Heart Association.

  • Commentaries serve as a forum in which experts highlight and discuss articles (published here and elsewhere) that the editors of Circulation Research feel are of particular significance to cardiovascular medicine.

  • Commentaries are edited by Aruni Bhatnagar & Ali J. Marian.

  • © 2014 American Heart Association, Inc.

References

  1. 1.↵
    1. Kho C,
    2. Lee A,
    3. Jeong D,
    4. Oh JG,
    5. Chaanine AH,
    6. Kizana E,
    7. Park WJ,
    8. Hajjar RJ
    . SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477:601–605.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Tilemann L,
    2. Lee A,
    3. Ishikawa K,
    4. Aguero J,
    5. Rapti K,
    6. Santos-Gallego C,
    7. Kohlbrenner E,
    8. Fish KM,
    9. Kho C,
    10. Hajjar RJ
    . SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med. 2013;5:211ra159.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. MacLennan DH,
    2. Brandl CJ,
    3. Korczak B,
    4. Green NM
    . Amino-acid sequence of a Ca2++ Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature. 1985;316:696–700.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Meyer M,
    2. Schillinger W,
    3. Pieske B,
    4. Holubarsch C,
    5. Heilmann C,
    6. Posival H,
    7. Kuwajima G,
    8. Mikoshiba K,
    9. Just H,
    10. Hasenfuss G
    . Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92:778–784.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Yeh ET
    . SUMOylation and de-SUMOylation: wrestling with life’s processes. J Biol Chem. 2009;284:8223–8227.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Cheng J,
    2. Kang X,
    3. Zhang S,
    4. Yeh ET
    . SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell. 2007;131:584–595.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kang X,
    2. Qi Y,
    3. Zuo Y,
    4. Wang Q,
    5. Zou Y,
    6. Schwartz RJ,
    7. Cheng J,
    8. Yeh ET
    . SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell. 2010;38:191–201.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Dou H,
    2. Huang C,
    3. Singh M,
    4. Carpenter PB,
    5. Yeh ET
    . Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell. 2010;39:333–345.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Wang J,
    2. Schwartz RJ
    . Sumoylation and regulation of cardiac gene expression. Circ Res. 2010;107:19–29.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Zsebo K,
    2. Yaroshinsky A,
    3. Rudy JJ,
    4. Wagner K,
    5. Greenberg B,
    6. Jessup M,
    7. Hajjar RJ
    . Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res. 2014;114:101–108.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Jessup M,
    2. Greenberg B,
    3. Mancini D,
    4. Cappola T,
    5. Pauly DF,
    6. Jaski B,
    7. Yaroshinsky A,
    8. Zsebo KM,
    9. Dittrich H,
    10. Hajjar RJ
    ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–313.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Wang YT,
    2. Chuang JY,
    3. Shen MR,
    4. Yang WB,
    5. Chang WC,
    6. Hung JJ
    . Sumoylation of specificity protein 1 augments its degradation by changing the localization and increasing the specificity protein 1 proteolytic process. J Mol Biol. 2008;380:869–885.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Spengler ML,
    2. Brattain MG
    . Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription. J Biol Chem. 2006;281:5567–5574.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Okura T,
    2. Gong L,
    3. Kamitani T,
    4. Wada T,
    5. Okura I,
    6. Wei CF,
    7. Chang HM,
    8. Yeh ET
    . Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol. 1996;157:4277–4281.
    OpenUrlAbstract
  15. 15.↵
    1. Ma Y,
    2. Chen Y,
    3. Yang Y,
    4. Chen B,
    5. Liu D,
    6. Xiong Z,
    7. Zhang C,
    8. Dong Y
    . Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression. Biochem Pharmacol. 2013;85:223–233.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
May 9, 2014, Volume 114, Issue 10
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Introduction
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Wrestling With Heart Failure
    Pimprapa Vejpongsa and Edward T.H. Yeh
    Circulation Research. 2014;114:1561-1563, originally published May 8, 2014
    https://doi.org/10.1161/CIRCRESAHA.114.304125

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Wrestling With Heart Failure
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Wrestling With Heart Failure
    Pimprapa Vejpongsa and Edward T.H. Yeh
    Circulation Research. 2014;114:1561-1563, originally published May 8, 2014
    https://doi.org/10.1161/CIRCRESAHA.114.304125
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Congenital Heart Disease
  • Basic, Translational, and Clinical Research
    • Contractile Function
    • Gene Therapy
    • Calcium Cycling/Excitation-Contraction Coupling
    • Animal Models of Human Disease

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured